WHO/ECDC frequently asked questions for Oseltamivir Resistance
15 February 2008
- Q1. How did WHO, the European Commission, the ECDC (European Centre for Disease Prevention and Control) and the European Medicines Agency learn about oseltamivir resistance in influenza viruses?
- Q2. Has oseltamivir resistance been found in other countries this influenza season?
- Q3. Have other types of influenza viruses tested resistant to oseltamivir?
- Q4. Is this a new problem?
- Q5. Did resistance develop because patients in Norway and other countries were taking oseltamivir?
- Q6. Is there an explanation for the high frequency of oseltamivir resistance?
- Q7. Did the patients with resistant viruses have any links to one another?
- Q8. What sort of illness has been associated with the resistant viruses?
- Q9. How easily are oseltamivir resistant viruses transmitted between people?
- Q10. How does resistance affect oseltamivir's activity against the influenza virus?
- Q11. Are there other drugs that can be used to treat oseltamivir resistant H1N1 virus infection?
- Q12. Is this season’s influenza vaccine effective against oseltamivir resistant strains?
- Q13. Do the oseltamivir resistant viruses pose any risk to cause a pandemic?
- Q14. What potential implications could the findings of oseltamivir resistance among seasonal viruses have for the treatment of H5N1 cases?
- Q15. What implications does oseltamivir resistance in seasonal H1N1 viruses have for the avian influenza H5N1?
- Q16. What is being done about the situation?
- Q17. What is going to happen? Is the oseltamivir resistant strain of H1N1 likely to become the predominant strain of H1N1 worldwide this influenza season?
- Q18. How can I protect myself and my family from seasonal influenza ?
- Q19. What are the implications of this development for antiviral stockpiles?
On 25 January 2008, the Norwegian authorities officially notified their EU partners and WHO, via the International Health Regulations (IHR) mechanism and the European Early Warning and Response System (EWRS) about a high rate of resistance to an antiviral drug, oseltamivir (Tamiflu©) in seasonal influenza A(H1N1) viruses. Of 16 virus isolates tested, 12 (75%) were resistant to oseltamivir. All the viruses were collected from patients earlier in the influenza season in November and December 2007 in Norway. Testing had been undertaken by National Institute of Public Health, the European Surveillance Network for Vigilance Against Viral Resistance (VIRGIL), the WHO Collaborating Center (CC) at the MRC National Institute for Medical Research in London and the European Influenza Surveillance Scheme (EISS).
Yes, oseltamivir resistant H1N1 viruses have been identified in other countries this season. Testing by the VIRGIL through the EISS Network and ECDC, the WHO London CC, and National Influenza Centers (NICs) has found widely varying prevalences (0 to >60%) of H1N1 resistance among European countries (EU, EEA, EFTA countries), with Norway and France showing the highest levels to date. Weekly updates on European resistance patterns are being posted on ECDC’s website.
WHO has sought further information from participants in its Global Influenza Surveillance Network (GISN) to assess the extent of circulation of oseltamivir-resistant viruses globally. None of the H1N1 isolates tested by the WHO CC in Tokyo or by China's Special Administrative Area of Hong Kong NIC were oseltamivir resistant last season (2006-7) or during the early part of the current season. The WHO CC at the Centers for Disease Control and Prevention in the United States has reported an 8% prevalence of resistance in H1N1 samples tested to date, and a similar prevalence of resistance has been detected in Canada. No resistance has been reported from Korea or New Zealand to date; two resistant variants detected in Australia were considered to be due to imported infections in travelers. However, resistance has been detected in some initially unaffected areas like Hong Kong among H1N1 isolates collected subsequently this season.
The available data indicate that oseltamivir resistance in H1N1 viruses is geographically variable both within Europe and globally. However, the distribution globally is not yet fully characterized and will likely change with time. Weekly updates on the global patterns of H1N1 oseltamivir resistance are posted on the GISN website .
The elevated resistance to oseltamivir appears currently limited to seasonal H1N1 viruses and does not involve circulating H3N2 or influenza B viruses. All of the resistant H1N1 viruses in Europe have a specific resistance mutation in the viral neuraminidase (i.e., a histidine to tyrosine substitution at amino acid 274). Influenza H1N1 has been the predominant influenza A virus circulating (with a smaller contribution of influenza B viruses) in many countries in Europe and other parts of the northern hemisphere this season, but influenza A H3N2 or a mixture of A and B viruses have circulated in other countries. Furthermore, patterns may change as the season progresses Updates are available at Seasonal influenza activity in the world, 2008.
Yes, the elevated prevalence of oseltamivir resistance in circulating H1N1 viruses in multiple countries is new. Resistance to oseltamivir in influenza viruses circulating in the community has been found before but at much lower levels. Past surveillance studies have found rates typically ranging from 0% to <0.5%. The highest rate of oseltamivir resistance that had been reported previously for surveillance of community isolates was in Japan during 2005-06 when 2.2 % of 178 H1N1 isolates were found to be resistant. During the last winter season (2006-7), no resistant H1N1 variants were detected in isolates from Japan or Europe, and less than 1% of U.S. H1N1 isolates showed oseltamivir resistance.
However, oseltamivir resistance is well-documented to emerge in persons being treated with the drug. In clinical studies, H1N1 viruses with this particular mutation have been detected in up to 16% of H1N1-infected children treated with oseltamivir. Typically, the resistant strains have emerged 3 to 6 days after treatment was begun but were not detected a few days later. However, past studies found little evidence of spread of resistant H1N1 virus to contacts or circulation within the community. The oseltamivir-resistant H1N1 viruses observed this year are different in that they are able to transmit from person to person.
None of the patients in Norway or elsewhere in Europe were reported either to have taken oseltamivir beforehand or have been exposed to people who had taken oseltamivir. The lack of drug treatment is not unexpected since oseltamivir is not often prescribed by doctors in most European countries.
The frequency of oseltamivir resistance in H1N1 viruses in the current influenza season is unexpected and the reason why a high percentage of these viruses are resistant is currently unknown. Available information does not indicate selective drug pressure is driving the development of resistance since few of the patients are known to have taken oseltamivir. Influenza viruses are continuously changing and it is possible that a resistant strain has emerged spontaneously or has continued to spread in the community after being selected initially in someone treated with oseltamivir. Further detailed laboratory characterization of circulating H1N1 viruses and epidemiological information on patients will be needed to help answer this question.
No. Preliminary investigations so far suggest that most of the persons with resistant viruses were not in contact or linked to each other or limited to a particular geographic location in a country. Not surprisingly, several household contacts affected by resistant H1N1 virus have been recognized. In general, patients in Norway or most other affected countries were not known to have traveled to other countries before becoming ill. These findings are consistent with this virus strain circulating at community level in some European and other countries.
Information is limited at present, but there is no evidence that the resistant viruses are causing more or less severe illness than other influenza viruses. The Norwegian patients appear to have had typical influenza illness. Three of them were hospitalized and later discharged. Oseltamivir-resistant H1N1 viruses, similar to other seasonal influenza viruses, can cause severe disease and fatalities among vulnerable people such as infants and the elderly. However, influenza seasons in which H1N1 viruses predominate typically are associated with less severe illness and lower mortality overall than seasons in which H3N2 viruses are predominant.
The available evidence indicates that these oseltamivir-resistant H1N1 viruses are transmissible from one person to another, but there is no evidence that the resistant H1N1 viruses are more transmissible between people than susceptible ones. Past studies in Japan suggested that low-level community transmission may occur with H1N1 viruses possessing the same resistance mutation that has been found in these recent cases. H1N1 viruses with this mutation are transmissible between laboratory animals.
Oseltamivir is an antiviral drug that blocks influenza viruses from spreading in the respiratory tract. The current resistant H1N1 viruses have been found to contain a specific mutation that makes them highly resistant to oseltamivir. This means that oseltamivir would most likely be ineffective for treating or preventing infections caused by these resistant H1N1 strains, although the drug will be effective against other influenza virus infections.
To date all the oseltamivir-resistant H1N1 isolates this season have been fully susceptible to the other available antiviral drugs, zanamivir and the adamantanes (amantadine and rimantadine). These would be alternative drugs for prevention or treatment of oseltamivir-resistant H1N1 infections.
However, almost all influenza H3N2 viruses and, in some parts of the world, many H1N1 viruses are now resistant to the adamantane drugs. Consequently, effective use of these drugs would depend on knowledge of local patterns of circulating strains and their antiviral susceptibilities.
The oseltamivir resistance mutation does not affect the vaccine's effectiveness, and there are no differences in antigenic properties between resistant and susceptible H1N1 viruses. Antiviral susceptibility and influenza vaccine effectiveness are based on different mechanisms. So far this influenza season, A(H1N1) viruses are predominant in most parts of northern hemisphere, and the majority are antigenically similar to A/Solomon Islands/3/2006, a vaccine virus, although an increasing proportion of recent H1N1 isolates have been antigenically distinguishable from the vaccine strain. Immunization with this season's vaccine remains an effective means of prevention against illness due to influenza viruses and should be comparably protective against oseltamivir-resistant and -susceptible H1N1 viruses.
No, human seasonal H1N1 viruses, including those with a resistance mutation, do not have the potential to cause a pandemic. The current type of human H1N1 viruses have been circulating widely in the population for many years.
Oseltamivir resistance due to the same mutation has been reported in three patients with H5N1 infection who were treated with oseltamivir. There are no reports of persons acquiring H5N1 infection from a patient with an oseltamivir resistant H5N1 virus.
The implications are uncertain at this point. The neuraminidase protein in human H1N1 viruses is different from that in avian H5N1 viruses. Until we learn why the unexpected increase in oseltamivir resistance has occurred in H1N1 viruses, it is too early to know what, if any, potential there might be for a similar increase in resistance to occur in H5N1 viruses. Furthermore, H5N1 viruses have not shown the ability to spread efficiently from person-to-person. WHO has not changed any of its recommendations regarding H5N1 treatment and preparations. A resistant human H1N1 virus could theoretically give its neuraminidase gene to an oseltamivir susceptible avian H5N1 virus if both viruses were to infect the same host. This is one way in which a resistant H5N1 could develop. However, none of the H5N1 viruses recovered from people have shown any evidence of such gene swapping to date. H5N1 viruses made from combinations of human and avian virus genes do not transmit or transmit very poorly in laboratory studies. Furthermore, H5N1 viruses have not shown the ability to spread efficiently from person-to-person.
WHO, the European Commission and ECDC and other organizations worldwide are working together to gather additional information on antiviral resistance in H1N1 viruses. The Collaborating Centers in WHO's Global Influenza Surveillance Network (GISN) and the VIRGIL Network and the European Influenza Surveillance Scheme perform testing and share the results of antiviral susceptibility data on seasonal human viruses and H5N1 isolates. WHO is also consulting with a variety of experts to assess the public health implications of these findings and the possible need for additional guidance. ECDC has published an interim Risk Assessment, which is available at: http://ecdc.europa.eu/pdf/080127_os.pdf. WHO, the European Commission and ECDC will continue to collaborate in monitoring the situation carefully, seeking advice from experts, and providing updated information as it becomes available. As indicated above, weekly updates on global H1N1 resistance patterns are being posted on the WHO website, and a summary page linking all the documents is on ECDC’s web-site.
It is simply too early to know. Information to date indicates that the resistant virus is transmissible from person-to-person and that these viruses continue to circulate in some countries. However, the prevalence of resistant viruses varies widely in European and other countries. They are predominant only in Norway at present. Thus, it is possible that the resistant strain will not become more common in other countries this season or continue to circulate in future seasons. Careful monitoring will be required throughout the rest of the season to follow the situation globally.
Seasonal influenza vaccination is the primary means of influenza prevention.
Following national guidance, people in high-risk groups for influenza complications (i.e older persons, those with chronic conditions, etc) should get vaccinated against influenza, if they have not already done so.
- Seasonal vaccines are effective for those who wish to reduce their risk of influenza and some countries advise use in travelers to influenza-affected countries.
People can also take steps to reduce the spread of influenza:
- Where possible, people infected with influenza should avoid close contact with others
- Basic hygiene measures, particularly covering coughs and sneezes and hand-washing, are likely effective in reducing the spread of influenza
Antiviral drugs that are active against seasonal influenza viruses, including the resistant H1N1 virus, are available in many countries.
The current H1N1 viruses are not a threat to cause a pandemic, and the cause and timing of the next influenza pandemic cannot be accurately predicted. Existing neuraminidase inhibitors, including oseltamivir, are useful against a range of influenza viruses, and oseltamivir resistance has been very uncommon in H5N1 viruses to date. WHO and its partners will continue to carefully monitor antiviral susceptibility patterns in seasonal and animal influenza viruses. WHO is not making changes to its general advice on antiviral stockpiling for the time being.